CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Insight Molecular Diagnostics CEO Josh Riggs reported a compensation-related stock transaction involving restricted stock units (RSUs). On March 26, 2026, 47,170 RSUs vested and were converted into the same number of common shares at an exercise price of $0.00 per share under the company’s 2018 Equity Incentive Plan.

To cover required tax withholding on this vesting, 12,310 common shares were withheld by the company at $4.11 per share. The filing states that Riggs did not sell any shares; the disposition was solely for tax obligations. Following these transactions, he directly held 38,365 common shares, and the remaining 75% of the original RSU award is scheduled to vest in equal installments over the next three years, subject to continuous service.

Insider Trade Summary

47,170 shares exercised/converted

Mixed 3 txns

Insider Riggs Josh

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	47,170	$0.00	--
Exercise	Common Stock	47,170	$0.00	--
Tax Withholding	Common Stock	12,310	$4.11	$51K

Holdings After Transaction: Restricted Stock Units — 141,509 shares (Direct); Common Stock — 50,675 shares (Direct)

Footnotes (1)

Represents vesting of restricted stock units ("RSUs") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs vested on the one-year anniversary of the effective date of grant. The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares. Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date.

Key Figures

RSUs vested and exercised: 47,170 shares Shares withheld for taxes: 12,310 shares Tax withholding price: $4.11 per share +3 more

6 metrics

RSUs vested and exercised 47,170 shares RSUs converted to common stock on March 26, 2026

Shares withheld for taxes 12,310 shares Withheld by company to cover tax obligations on vesting

Tax withholding price $4.11 per share Value used for shares withheld to satisfy tax liability

Shares held after transactions 38,365 shares CEO’s direct common stock holdings following vesting and withholding

Exercise price of RSUs $0.00 RSUs converted into common stock at no cash exercise price

RSU vesting portion 25% initial vesting First tranche vested on March 26, 2026; 75% remains scheduled

Key Terms

Restricted Stock Units, 2018 Equity Incentive Plan, tax withholding obligations, continuous service, +1 more

5 terms

Restricted Stock Units financial

"Represents vesting of restricted stock units ("RSUs") issued pursuant to the Company's 2018 Equity Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2018 Equity Incentive Plan financial

"RSUs issued pursuant to the Company's 2018 Equity Incentive Plan."

tax withholding obligations financial

"shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs."

continuous service financial

"remaining 75% will vest in equal installments ... subject to continuous service through the applicable vesting date."

vesting financial

"25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

03/30/2026 - 05:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riggs Josh

(Last)

(First)

(Middle)

C/O INSIGHT MOLECULAR DIAGNOSTICS INC.

2 INTERNATIONAL PLAZA, SUITE 510

(Street)

NASHVILLE

TENNESSEE

37217

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/26/2026		M		47,170	A	⁽¹⁾	50,675	D
Common Stock	03/26/2026		F		12,310⁽²⁾	D	$4.11	38,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	03/26/2026		M			47,170	⁽³⁾	⁽³⁾	Common Stock	47,170	$0	141,509	D

Explanation of Responses:

1. Represents vesting of restricted stock units ("RSUs") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs vested on the one-year anniversary of the effective date of grant.

2. The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares.

3. Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date.

	/s/ Josh Riggs	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did IMDX CEO Josh Riggs report in this Form 4 filing?

Josh Riggs reported the vesting and conversion of 47,170 restricted stock units into common shares. The transaction was part of Insight Molecular Diagnostics’ 2018 Equity Incentive Plan and reflects routine equity compensation rather than an open-market stock purchase or sale.

How many Insight Molecular (IMDX) RSUs vested for the CEO?

A total of 47,170 restricted stock units vested for CEO Josh Riggs. Each RSU represents one share of common stock, issued under the 2018 Equity Incentive Plan, and 25% of this RSU award vested on March 26, 2026, with the remainder vesting over three additional years.

Did the IMDX CEO sell any shares in this Form 4 transaction?

No, the filing explicitly states the CEO did not sell any shares. Instead, 12,310 shares were withheld by the company to satisfy required tax withholding obligations associated with the RSU vesting, which is a standard non-market mechanism for covering tax liabilities.

Why were 12,310 IMDX shares disposed of in the Form 4?

The 12,310-share disposition reflects shares withheld to cover tax withholding obligations on the RSU vesting. The filing explains that these shares were delivered to the company for taxes, so the CEO did not conduct any open-market sale or discretionary trading in Insight Molecular stock.

What is the vesting schedule of the IMDX CEO’s RSUs?

According to the filing, 25% of the RSUs vested on March 26, 2026. The remaining 75% will vest in equal installments on the second-, third-, and fourth-year anniversaries of the grant’s effective date, contingent on the CEO’s continuous service with the company.

How many IMDX common shares does the CEO hold after these transactions?

After the RSU vesting and related tax withholding, CEO Josh Riggs directly holds 38,365 common shares. This figure reflects the net position after 47,170 shares were issued from vested RSUs and 12,310 of those shares were withheld by Insight Molecular Diagnostics to satisfy tax obligations.